BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 30882253)

  • 1. What should we tackle next in acute myeloid leukemia? Wilms tumor gene 1 vaccine therapy would be a promising and versatile strategy for acute myeloid leukemia.
    Nakata J; Oji Y; Oka Y; Sugiyama H
    Expert Rev Hematol; 2019 Apr; 12(4):211-213. PubMed ID: 30882253
    [No Abstract]   [Full Text] [Related]  

  • 2. WT1 vaccination in acute myeloid leukemia: new methods of implementing adoptive immunotherapy.
    Rein LA; Chao NJ
    Expert Opin Investig Drugs; 2014 Mar; 23(3):417-26. PubMed ID: 24521058
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical Grade Production of Wilms' Tumor-1 Loaded Cord Blood-Derived Dendritic Cells to Prevent Relapse in Pediatric AML After Cord Blood Transplantation.
    Plantinga M; Lo Presti V; de Haar CG; Dünnebach E; Madrigal A; Lindemans CA; Boelens JJ; Nierkens S
    Front Immunol; 2020; 11():559152. PubMed ID: 33101274
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Wilms' tumor gene 1 transcript levels in leukapheresis of peripheral blood hematopoietic cells predict relapse risk in patients autografted for acute myeloid leukemia.
    Messina C; Candoni A; Carrabba MG; Tresoldi C; Sala E; Tassara M; Crippa A; Peccatori J; Assanelli A; Gattillo S; Bellio L; Fanin R; Ciceri F; Bernardi M
    Biol Blood Marrow Transplant; 2014 Oct; 20(10):1586-91. PubMed ID: 24954546
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Two distinct effector memory cell populations of WT1 (Wilms' tumor gene 1)-specific cytotoxic T lymphocytes in acute myeloid leukemia patients.
    Nakae Y; Oka Y; Fujiki F; Morimoto S; Kamiya T; Takashima S; Nakata J; Nishida S; Nakajima H; Hosen N; Tsuboi A; Kyo T; Oji Y; Mizuguchi K; Kumanogoh A; Sugiyama H
    Cancer Immunol Immunother; 2015 Jul; 64(7):791-804. PubMed ID: 25835542
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Wilms Tumor 1 Expression and Pre-emptive Immunotherapy in Patients with Acute Myeloid Leukemia Undergoing an Allogeneic Hemopoietic Stem Cell Transplantation.
    Di Grazia C; Pozzi S; Geroldi S; Grasso R; Miglino M; Colombo N; Tedone E; Luchetti S; Lamparelli T; Gualandi F; Ibatici A; Bregante S; Van Lint MT; Raiola AM; Dominietto A; Varaldo R; Galaverna F; Ghiso A; Sica S; Bacigalupo A
    Biol Blood Marrow Transplant; 2016 Jul; 22(7):1242-1246. PubMed ID: 26970379
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Correlation of minimal residual disease by assessing Wilms tumor gene expression and engraftment by variable number of tandem repeats in children with leukemia posthematopoietic stem cell transplantation.
    Olszewski M; Chou PM; Huang W; Tallman S; Kletzel M
    Pediatr Dev Pathol; 2006; 9(3):203-9. PubMed ID: 16944968
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Potential of dendritic-cell immunotherapy for relapse after allogeneic hematopoietic stem cell transplantation, shown by WT1 peptide- and keyhole-limpet-hemocyanin-pulsed, donor-derived dendritic-cell vaccine for acute myeloid leukemia.
    Kitawaki T; Kadowaki N; Kondo T; Ishikawa T; Ichinohe T; Teramukai S; Fukushima M; Kasai Y; Maekawa T; Uchiyama T
    Am J Hematol; 2008 Apr; 83(4):315-7. PubMed ID: 18081032
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Reduction in WT1 gene expression during early treatment predicts the outcome in patients with acute myeloid leukemia.
    Andersson C; Li X; Lorenz F; Golovleva I; Wahlin A; Li A
    Diagn Mol Pathol; 2012 Dec; 21(4):225-33. PubMed ID: 23111196
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Induction of WT1 (Wilms' tumor gene)-specific cytotoxic T lymphocytes by WT1 peptide vaccine and the resultant cancer regression.
    Oka Y; Tsuboi A; Taguchi T; Osaki T; Kyo T; Nakajima H; Elisseeva OA; Oji Y; Kawakami M; Ikegame K; Hosen N; Yoshihara S; Wu F; Fujiki F; Murakami M; Masuda T; Nishida S; Shirakata T; Nakatsuka S; Sasaki A; Udaka K; Dohy H; Aozasa K; Noguchi S; Kawase I; Sugiyama H
    Proc Natl Acad Sci U S A; 2004 Sep; 101(38):13885-90. PubMed ID: 15365188
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Significant co-expression of WT1 and MDR1 genes in acute myeloid leukemia patients at diagnosis.
    Galimberti S; Guerrini F; Carulli G; Fazzi R; Palumbo GA; Morabito F; Petrini M
    Eur J Haematol; 2004 Jan; 72(1):45-51. PubMed ID: 14962262
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Role of Sequential Monitoring of WT1 Gene Expression in Patients With Acute Myeloid Leukemia for the Early Detection of Leukemia Relapse.
    Mashima K; Oh I; Ikeda T; Toda Y; Ito S; Umino K; Minakata D; Nakano H; Morita K; Yamasaki R; Kawasaki Y; Sugimoto M; Yamamoto C; Ashizawa M; Fujiwara SI; Hatano K; Sato K; Omine K; Muroi K; Kanda Y
    Clin Lymphoma Myeloma Leuk; 2018 Dec; 18(12):e521-e527. PubMed ID: 30181104
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Low WT1 transcript levels at diagnosis predicted poor outcomes of acute myeloid leukemia patients with t(8;21) who received chemotherapy or allogeneic hematopoietic stem cell transplantation.
    Qin YZ; Wang Y; Zhu HH; Gale RP; Zhang MJ; Jiang Q; Jiang H; Xu LP; Chen H; Zhang XH; Liu YR; Lai YY; Jiang B; Liu KY; Huang XJ
    Chin J Cancer; 2016 May; 35():46. PubMed ID: 27197573
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Wilms' Tumor Gene 1 (WT1) Peptide Vaccine Therapy for Hematological Malignancies: From CTL Epitope Identification to Recent Progress in Clinical Studies Including a Cure-Oriented Strategy.
    Oka Y; Tsuboi A; Nakata J; Nishida S; Hosen N; Kumanogoh A; Oji Y; Sugiyama H
    Oncol Res Treat; 2017; 40(11):682-690. PubMed ID: 29041012
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [WT1-targeting cancer vaccine].
    Sugiyama H
    Nihon Rinsho; 2012 Dec; 70(12):2105-13. PubMed ID: 23259381
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Combinatorial molecular marker assays of WT1, survivin, and TERT at initial diagnosis of adult acute myeloid leukemia.
    Kim HJ; Choi EJ; Sohn HJ; Park SH; Min WS; Kim TG
    Eur J Haematol; 2013 Nov; 91(5):411-22. PubMed ID: 23826993
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Use of Wilms Tumor 1 Gene Expression as a Reliable Marker for Prognosis and Minimal Residual Disease Monitoring in Acute Myeloid Leukemia With Normal Karyotype Patients.
    Marjanovic I; Karan-Djurasevic T; Ugrin M; Virijevic M; Vidovic A; Tomin D; Suvajdzic Vukovic N; Pavlovic S; Tosic N
    Clin Lymphoma Myeloma Leuk; 2017 May; 17(5):312-319. PubMed ID: 28163010
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prognostic implications of Wilms' tumor gene (WT1) expression in patients with de novo acute myeloid leukemia.
    Barragán E; Cervera J; Bolufer P; Ballester S; Martín G; Fernández P; Collado R; Sayas MJ; Sanz MA
    Haematologica; 2004 Aug; 89(8):926-33. PubMed ID: 15339675
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [WT1 peptide-based immunotherapy].
    Sugiyama H
    Nihon Rinsho; 2005 Jun; 63(6):1101-9. PubMed ID: 15948398
    [TBL] [Abstract][Full Text] [Related]  

  • 20. WT1 vaccination in AML and MDS: A pilot trial with synthetic analog peptides.
    Brayer J; Lancet JE; Powers J; List A; Balducci L; Komrokji R; Pinilla-Ibarz J
    Am J Hematol; 2015 Jul; 90(7):602-7. PubMed ID: 25802083
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.